PFE vs TERN

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Score Change Explanation: The drastic score reduction from 70/100 to 10/100 is due to the fundamental change in Terns Pharmaceuticals' investment profile. On March 25, 2026, Merck agreed to acquire TERN for $53/share cash. This acquisition eliminates TERN's independent 10x growth potential, which was the core thesis of the previous analysis. For existing shareholders, the upside is now capped at t...